Modified Welsh regimen: a promising therapy for actinomycetoma.

Area of Science:

• Dermatology
• Infectious Diseases
• Medical Mycology

Background:

• Mycetoma is a neglected fungal infection causing significant morbidity, particularly in India.
• Treatment of actinomycotic mycetoma presents challenges for dermatologists.
• Previous therapies have shown limited efficacy in some patients.

Purpose of the Study:

• To evaluate the efficacy of a novel combination therapy for actinomycotic mycetoma.
• To assess a treatment regimen for patients resistant to standard therapies.

Main Methods:

• A prospective study included 18 patients diagnosed with actinomycetoma and poor response to prior treatments.
• Patients received a combination therapy: amikacin, cotrimoxazole (Welsh regimen), plus rifampicin.
• Clinical evaluation involved radiological and laboratory investigations.

Main Results:

• Sixteen out of 18 patients completed the triple-drug combination therapy.
• The treatment resulted in clinical remission for 16 patients.
• No recurrence of actinomycotic mycetoma was observed in the 16 patients during an 18-month follow-up period.

Conclusions:

• The combination therapy of amikacin, cotrimoxazole, and rifampicin is a promising treatment for actinomycotic mycetoma.
• This regimen offers a potential solution for patients with difficult-to-treat or recurrent mycetoma.
• Further research is warranted to confirm these findings in larger cohorts.